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Abstract
Background: The Pan American Health Organization provides technical cooperation to countries in Latin America
and the Caribbean for the scale-up of HIV care and treatment based on the Treatment 2.0 initiative. Fourteen Joint
Review Missions (JRMs) were conducted between March 2012 and October 2014. Evaluating the degree of
implementation of the recommendations of the JRMs and their impact on health policies, would help countries
identify their gaps and areas for priority interventions.
Methods: A descriptive analysis of the JRM recommendations was conducted for eight countries. An in-depth
cross-sectional retrospective analysis of the degree of implementation of these recommendations in Ecuador,
Venezuela, Bolivia, and El Salvador was performed through a standardized self-administered questionnaire applied
to key informants. A comparative quantitative analysis on the optimization of antiretroviral regimens ‘before/after’
JRMs was conducted in three of the latter four countries, using data reported in 2013 and 2014.
Results: The priority areas with most recommendations were the optimization of antiretroviral treatment (ART)
regimens (n = 57), the rational and efficient use of resources (n = 27) and the provision of point-of-care diagnostics
and monitoring tools (n = 26), followed by community mobilization (n = 23), strategic information (n = 17) and the
adaptation of delivery services (n = 15). The in-depth analysis in four countries showed that the two priority areas
where most progress was observed were the rational and efficient use of resources (62 %) and the optimization of
ART regimens (60 %). Adaptation of delivery services, community mobilization and strategic information were rated
at 52 % and the provision of point-of-care diagnostics and monitoring tools 38 %. The quantitative analysis on
optimization evidenced a 36 % reduction in the number of first-line and second-line ART regimens, a 5.4 % increase
in the proportion of patients on WHO-recommended first-line regimens, a 19.4 % increase in the use of the WHO
preferred first-line regimen, 51 % increase in the use of WHO-recommended second-line regimens, and a significant
reduction in the use of obsolete drugs in first- and second-line regimens (respectively 1 and 9 % of regimens in 2013).
Conclusions: A relatively good level of progress was perceived in the recommendations related to optimization of ART
regimens. Challenges remain on the improvement of recommendations related to health system strengthening and
the promotion and support aimed at community-based organizations as part of the response to HIV/AIDS in Latin
America. The JRMs are a useful mechanism for providing coherent technical support to guide countries in the pursuit
of a comprehensive response to HIV/AIDS in the Latin American region.
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Background
By the end of 2013 approximately 35 million people
were living with HIV (PLHIV) worldwide. Of these, 19
million were unaware that they were HIV-positive, while
approximately 13 million were receiving antiretroviral
therapy (ART). Of the estimated 1.6 million PLHIV in
Latin America by the end of 2013, 70 % had been
diagnosed, 44 % of eligible adults (15+ years) and 64 %
of the children aged between 0 and 14 years were on
ART (2013 World Health Organization [WHO] eligible
criteria). Although ART coverage in this Region is the
highest among the world’s low and middle-income
countries (45 %), rates vary from country to country ran-
ging from 20–64 % (Bolivia and Barbados respectively)
[1, 2] and 35 % of new infections are diagnosed late
(<200 CD4 cells/μl) [3].
Treatment 2.0 was introduced in June 2010 as an ini-
tiative of the WHO and the United Nations Program on
HIV/AIDS (UNAIDS) designed to promote the scale-up
and sustainability of HIV treatment by enhancing the
efficiency and impact of treatment and care programs in
countries with limited resources. The initiative responds
to the financial and technical challenges that continue to
limit universal access to ART [4].
This initiative is intended to guide countries to reach
and sustain universal access to HIV treatment and to
maximize the preventive benefits of ART through
focused work in five interrelated priority areas: opti-
mization of ART regimens, provision of accessible point-
of-care (POC) diagnostics and monitoring tools, rational
and efficient use of resources, adaptation of delivery sys-
tems and community mobilization. These priority areas are
interdependent and form a strategic framework for guiding
the implementation of the initiative in countries [5].
The concepts of simplification, standardization, commu-
nity mobilization, and reducing costs are based on the
principles derived from WHO’s public health approach to
universal access to ART, as well as on scientific evidence
and best practices resulting from the implementation of
HIV programs [6]. The Treatment 2.0 initiative fits within
the UNAIDS Strategy 2011–2015 and the WHO Global
Health Sector Strategy on HIV/AIDS 2011–2015 [7, 8].
The expected long term impact of the implementation of
this initiative is reduction of morbidity and mortality, as
well as the number of new HIV infections. According to
UNAIDS-WHO estimates, ten million deaths could be
prevented by 2025 [9]. It was recently demonstrated that
the effective use of ART is associated with a 96 % risk
reduction of sexual transmission of HIV among sero-
discordant heterosexual couples as a result of viral sup-
pression in the infected patient. This reinforces new
concepts such as prevention benefits of ART, especially
when initiated early after HIV infection [10]. If all individ-
uals needing treatment could initiate ART and maintain
an undetectable viral load, a third of new HIV infections
could be prevented [5, 11].
Engaging the full participation of PLHIV and affected
communities in order to sustain the achievements and
increase ART coverage rate in the Latin American region
is a priority. This will contribute to achieve the com-
mitments made during the 2011 UN General Assembly
High Level Meeting on AIDS as well as the new regional
care and treatment targets by 2020: 90 % of PLHIV diag-
nosed; 90 % of eligible people receiving ART; and 90 %
of people on ART achieving viral suppression [12].
In recent years Latin American countries have begun
to apply the principles of the Treatment 2.0 initiative in
their health care programs. The Treatment 2.0 action
framework reflects the need to achieve concrete results
through simultaneous improvements in each of the
initiative’s priority areas. Effective and strategic collabor-
ation between the broad range of stakeholders in the re-
sponse to HIV is a necessity. The Pan American Health
Organization (PAHO) has been supporting this process
through various mechanisms among them, working with
institutions such as The Council of Ministers of Health of
Central America (COMISCA), The Andean Organism for
Health (ORAS), the Pan Caribbean Partnership against
HIV/AIDS (PANCAP) and the Horizontal Technical
Cooperation Group (GCTH).
With technical guidance from PAHO, actions have
been pursued in the Region to roll out the Treatment
2.0 initiative. This has been done through various re-
gional consultations and consensus meetings on topics
related to ARV stock-outs, HIV testing and counseling,
expansion and sustainability of HIV treatment, strategic
information as well as the launch of the WHO 2013
consolidated guidelines on ARV drugs for Treatment and
Prevention of HIV infection, the WHO 2015 Consolidated
Guidelines on HIV testing services 2015 and two Latin
American Forums on HIV Care. A series of reports
entitled “ART in the Spotlight: a public health analysis in
Latin America and the Caribbean” have been published in
2013 and 2014 [3, 13]. In addition, a total of 14 Treatment
2.0 Joint Review Missions (JRMs) had been undertaken up
till October 2014: Ecuador (March 2012); Venezuela (May
2012); Bolivia (July 2012); El Salvador (January 2013); the
Dominican Republic (February 2013); Honduras (March
2013); Argentina (July 2013); Guatemala (October 2013);
Uruguay (November 2013); Nicaragua (March 2014);
Paraguay (March 2014); Panama (March 2014); Jamaica
(September 2014); and Costa Rica (October 2014).
Phases of the Joint Review Missions
The typical Treatment 2.0 JRMs format includes three-
phases: 1) a preparatory phase during which the team in
the country collects and analyzes data on the HIV situ-
ation in general and on ART in particular. To ensure
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broad inclusiveness, an opportunity is provided for in-
depth dialogue between national authorities and re-
presentatives of civil society and scientific communities;
2) the visits of an international team interacting with all
the key actors identified, to finalize the analysis of the
situation with special focus on the initiative’s five main
priority areas. Based on this situation analysis, visits are
prioritized to governmental and nongovernmental facil-
ities providing HIV care and treatment such as hospitals,
public health laboratories, pharmacies, national insti-
tutes of health, and interviews are held with key infor-
mants. At the end of the visit, the joint team develops
recommendations and a short and medium-term
national work plan for their implementation. The set of
the country visit conclusions are presented to the high-
est representatives of the Ministry of Health and the
National AIDS Program to ensure top-level support for
implementing the plan; 3) implementation and moni-
toring of the recommendations.
This study aims to examine the degree of implementa-
tion of the Treatment 2.0 initiative in Latin American
countries by analyzing to what extent the recommenda-
tions resulting from the JRMs have progressed, and assess
the impact of these recommendations on health policies.
Methods
Selection of countries
In order to assess the degree of implementation of the
recommendations, an overall descriptive analysis was
conducted among the first eight countries where PAHO
and partners undertook this type of review mission:
Ecuador, Venezuela, Bolivia, El Salvador, the Dominican
Republic, Honduras, Argentina, and Guatemala. An in-
depth cross-sectional analysis was also done in four
selected countries based on the following criteria: 1) a
mission conducted between 12 and 24 months prior to
this monitoring exercise; 2) willingness of the national
health authorities to participate in this exercise, and;
3) availability of different actors selected for the monitor-
ing exercise. A standardized questionnaire was designed
and used among one of each of the following key infor-
mants from each country: representative of the national
ART programs, representative of civil society linked to
ART programs in each country and a technical staff from
the PAHO/WHO representation office of each country.
The selected countries where this assessment was under-
taken were Ecuador, Venezuela, Bolivia, and El Salvador.
Standardized instrument and the measure of the
perception of progress of each recommendation
The standardized tool was designed to collect the informa-
tion related to the five priority areas of the Treatment 2.0
initiative [see Additional files 1 and 2]. The ‘strategic infor-
mation’ area was added due to its cross-cutting
importance in monitoring the implementation of the rec-
ommendations in each country. A color-coded ‘traffic
light’ measure was introduced to indicate the progress
made in each area, with red representing ‘implementation
not yet underway’, yellow ‘in progress’ and green ‘com-
pleted’. In addition, the measurement of the perception of
progress of each recommendation was scored on a numer-
ical scale based on the Likert scale, adapted to include dif-
ferent variables ranging from 0–5, where 0 = no progress
(0 %), 1 = very early stage (20 %), 2 = initiated (40 %), 3 =
in progress (60 %), 4 = at final stage (80 %), and 5 = com-
pleted (100 %) [14]. A column was also provided for com-
ments on the implementation of each recommendation.
The instrument was piloted by two local technical officers
of PAHO in countries were the instrument was not ap-
plied to evaluate comprehension and consistency. Results
were used to finalize the design of the tool. This standard-
ized instrument was sent to all the selected key informants
for self-completion.
A rating scale was established to measure the perception
of the interviewees regarding the progress in implement-
ing the recommendations of each priority area. For this, a
differential percentage weight for each recommendation
was applied to all priority areas, based on established
multi-criteria analytical decision-making methodologies
[15–17]. Two major factors were also taken into consider-
ation which affected the final attributed weight, the size of
the population to be covered by the activity (national,
regional or local), and the level of sustainability that the
recommendation would achieve in the country. After this
first classification was completed, the following sec-
ondary factors were applied in order of priority according
to attributed percentage weight: a) an activity that needed
to be undertaken prior to the other activities, and critical
to allow continuity; b) an activity of strategic importance
for formulating a national response and in line with inter-
national parameters; c) an intermediate activity that could
have national impact or seriously interfere in the national
process in the specific priority area; d) an intermediate
activity with no significant impact on the national re-
sponse or one that would not negatively impact the other
activities in the same priority area; e) a minor activity that
could impact on the national response and/or on the
implementation of other activities; f) a minor activity with
negligible impact on the other activities of the thematic
area. The percentage of compliance was calculated based
on the average score of recommendations for each priority
areas by each key informant from each organization
multiplied by the assigned percentage weight for each rec-
ommendation. Review of responses and all calculations
were done by two of the authors separately (FP, BG) to
assure compliance and validity. If different appreciations
were found, response results were reviewed and compared
and a final result was agreed upon. Incoherent answers
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were not considered after mutual agreement by the two
authors. Results of the percentage of compliance are
shown based on the number and type of recommenda-
tions by priority areas and country. When a priority area
and/or a key informant are not shown, this is because the
specific priority area did not have recommendation or the
key informant did not respond to the survey.
Quantitative analysis of the optimization of antiretroviral
drugs use
To complement the assessment, a quantitative analysis of
the optimization of antiretroviral drugs was conducted in
three of the four countries where the implementation
of the recommendations was systemically monitored
(Bolivia, El Salvador, and Venezuela). This analysis was
based on official data reported annually by the countries
in the WHO AIDS Medicines and Diagnostics Service
questionnaires regarding the use of antiretroviral
drugs for 2013 (referring to 2012) and 2014 (referring
to 2013) [3, 13, 18]. It was not possible to include
Ecuador in this analysis since the country did not report
in 2014. The aim was to document changes in the use of
antiretrovirals in the countries that had received the
Treatment 2.0 JRM, by conducting a comparative data
analysis of antiretroviral use in 2012 (before the mission)
and 2013 (after the mission). The following indicators
were considered in order to compare the average values of
the three countries in the two selected years: the number
of first-line ART regimens in use; the percentage of pa-
tients in first-line ART regimens recommended by WHO
(preferred and alternate); the percentage of patients in the
preferred first-line ART regimens recommended by WHO
(TDF + 3TC [or FTC] + EFV); the percentage of patients
in first-line ART regimens including obsolete antiretrovir-
als (ddl, d4T, IDV, NFV); the number of second-line ART
regimens in use; the percentage of patients in second-line
ART regimens recommended by WHO; and the percent-
age of patients in second-line ART regimens including ob-
solete ARVs.
We reviewed the need for ethics approval with the Pan
American Health Organization Ethics Committee who
confirmed that given the nature of the study (retrospective
survey through interviews) this work did not require
ethics approval. All participants were informed about the
study and provided oral informed consent to be included.
Privacy and confidentiality were maintained throughout
the study period; each questionnaire was number-coded
without any personal identification.
Results
Type and total number of recommendations per country
Ecuador and Bolivia received the highest number of rec-
ommendations (29 each), followed by Honduras (n = 28)
and Argentina (n = 20). The technical priority areas
where the largest number of recommendations were fo-
cused were those corresponding to optimization of ART
regimens (n = 57), followed by rational and efficient use
of resources (n = 27) and provision of POC diagnostics
and monitoring tools (n = 26) (Table 1). The review of
the type of recommendations most frequently included
in each technical priority area revealed the trends here
below:
Optimization of ART Regimens: the following recom-
mendations were present in the eight countries where the
monitoring was conducted: 1) to promote the use of regi-
mens of simplified, less toxic drugs that maintain thera-
peutic efficacy, thus pointing to the need of updating the
recommended therapeutic regimens with preferred first-
line treatment with TDF + 3TC (or FTC) + EFV in a fixed
dosage combination (FDC) for adults and adolescents;
2) the recommended second-line treatment should in-
clude two nucleoside reverse transcriptase inhibitors plus
a protease inhibitor reinforced with ritonavir (AZT/3TC
[CDF]) + ATV/r (or LPV/r) and; 3) the need to gradually
phase out ARVs due to their toxicity profile (e.g. stavudine
[d4T]) with a migration plan accompanied by an infor-
mation and communication strategy. In seven of the eight
countries, updating the national ART and treatment
guidelines (or finalizing this process) was recommended.
Provision of Access to POC Diagnostics and Monitoring
Tools four of the eight countries received the following
recommendations: 1) the need to develop and implement
HIV diagnosis strategies to include POC technologies that
would make it possible to expand HIV testing and coun-
seling, mainly at the primary and community level; 2) the
use and decentralization of the viral load test as the pre-
ferred method for confirming treatment effectiveness and
for diagnosis of treatment failure; 3) to decentralize the
use of CD4 as a method for evaluating eligibility for ART
and for patient monitoring.
Rational and efficient use of resources in seven of the
eight countries the following steps were recommended:
1) to adapt the drug and supply management plans con-
sidering the services available under the PAHO Strategic
Fund, which is a mechanism that facilitates the procure-
ment of strategic public health supplies and materials to
the Member States of the Region of the Americas; and
2) to review the methodology for estimating country
needs of drugs, supplies and laboratory tests.
Adapt Delivery Systems: the key recommendation in
this priority area was related to the need to deconcen-
trate, decentralize and integrate the ART program at all
levels of the healthcare system in four of the eight coun-
tries visited.
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Community Mobilization: two recommendations were
highlighted in this topic: 1) in five of the eight countries
there is a need to design and implement communication
strategies in order to provide information about the
Treatment 2.0 initiative and its priority areas in different
national contexts; 2) in three of eight countries it was
recommended to involve and engage key populations
and people living with HIV in the planning, delivery and
evaluation of HIV treatment and care programs. This
includes inter alia prevention interventions and support
for ART adherence.
Strategic Information: an identified need was to
strengthen the information systems in each country in
order to have a complete overview of the national cohort
of patients in care and treatment including the treatment
cascade and plan appropriate and timely interventions.
In some countries it is necessary to evaluate and make
necessary changes in the existing HIV information
systems (MANGUA in Guatemala, CENAVAFELS in
Venezuela, and SEGAMI in the Dominican Republic).
Results of the structured interviews
Overall, representatives from national ART program and
international cooperation from each of the four coun-
tries completed the questionnaire. Civil society re-
presentatives from Ecuador and El Salvador who were
identified and agreed to respond to the survey did not
submit the completed questionnaire even after various
reminders. The reason for this was not established. No
incoherent answers were found.
Analysis of the implementation of the Treatment 2.0
initiative in each country
Ecuador
Representatives of the National AIDS Program (NAP) and
PAHO responded to the survey for Ecuador. The percep-
tion of compliance with the recommendations for each pri-
ority area of the Treatment 2.0 initiative in Ecuador shows
that most progress was made on the optimization of ART
regimens (70–72 %), while the least progress was made on
the provision of implementing access to POC diagnostics
and monitoring tools (32 %). With the exception of the
optimization of ART regimens priority area, none of the
other priority areas exceeded 50 % in terms of perception
of their implementation (Fig. 1). When examining the
optimization of ART regimens priority area, the main
recommendation concerned updating the ARV treatment
guidelines, together with updating the first and second-
line standardized regimens and withdrawing non-
recommended drugs (Fig. 2). Finally, both the NAP and
PAHO representatives agreed with the perception that
little progress had been made in the POC diagnosis
priority area implementation (20–40 %) (data not
presented).
Venezuela
A representative of the NAP and international cooper-
ation representatives for Venezuela (PAHO and UNAIDS)
responded to the survey, while it was not possible to gauge
the opinion of civil society in order to complete the exer-
cise. The PNS considered that most progress had been
made in the community mobilization priority area (92 %),
followed by the rational and efficient use of resources
priority area (85 %). Meanwhile, representatives from the
international cooperation agreed that much progress was
evident in the rational and efficient use of resources and
optimization of ART regimens (both 70 %), followed by
community mobilization (60 %). A significant difference
between the respondents was observed in the perception
of progress in the adaption of delivery service priority
area: the NAP perceived a progress of 60 %, while inter-
national cooperation representatives cited that progress
was zero. (Fig. 1). Both key informants interviewed agreed
that progress on implementation of the recommendations
on strategic information was low (20 % NAP, 40 % inter-
national cooperation). The strategic information recom-
mendations were perceived by the interviewees to have
made limited progress (data not presented).
Bolivia
The monitoring survey for Bolivia was completed by
representatives of the NAP, PAHO and civil society. Fig. 3
illustrates the perception of the progress made by the
Table 1 Treatment 2.0 Joint Technical Missions in Latin America. Type and number of recommendations by country (2012–2013)
Technical areas Ecuador Venezuela Bolivia El Salvador Dominican Republic Honduras Argentina Guatemala Total
Optimize ART Regimens 10 6 8 10 4 6 5 8 57
Provide point-of-care diagnosis 6 3 4 0 1 8 3 1 26
Reduce costs: rational-efficient
use of resources
3 4 4 2 5 5 2 2 27
Adapt delivery systems 0 1 8 0 1 1 4 0 15
Mobilize communities 5 3 1 0 0 6 5 3 23
Strategic information 5 3 4 0 2 1 1 1 17
TOTAL 29 19 29 12 13 28 20 15 165
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Treatment 2.0 initiative in this country under each
priority area. Both NAP and PAHO had a general
perception of greater progress than was perceived by
civil society. Progress in the optimization of ART
regimens priority area scored an average of 79 %, while
rational and efficient use of resources was rated at 75 %.
The lowest average scores were in the provision of POC
diagnostics and monitoring tools (41 %) and community
mobilization (40 %) priority areas.
El Salvador
Representatives of the National AIDS Program, PAHO
and civil society responded to the survey for El Salvador.
There were no recommendations for the provision of
POC diagnostics and monitoring tools priority area, nor
for community mobilization. The area with most recom-
mendations was for the optimization of ART regimens
(n = 9), where all interviewees concurred that progress
had been made (average 55 %). On the other hand, there
Fig. 2 Perception of the compliance of the recommendations regarding the optimization of antiretroviral regimens by representatives of the
National AIDS Programof Ecuador and the country PAHO office*
Fig. 1 Follow-up of the Treatment 2.0 Strategy in Ecuador (29 recommendations)* and Venezuela (20 recommendations)±: perception of the
compliance of recommendations by key informants
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was a notable difference between the interviewees’
perception of progress in the two priority areas rational
and efficient use of resources and strategic information
(ranging from 20–100 %) (Fig. 3).
Comparative analysis of the implementation of each
priority area in the different countries
In the four countries where structured interviews were
conducted, most perceived progress was made in the
rational and efficient use of resources priority area where
average progress was perceived to be 62 %, followed by
the optimization of ART regimens priority area (average
59.7 %). Meanwhile, progress in the priority areas of the
adaption of delivery systems, community mobilization,
and strategic information were rated at 52 %. Finally, the
provision of POC diagnostics and monitoring tools
scored the lowest (an average of only 38 %).
The optimization of ART regimens priority area
received an overall average rating of 60 % progress in
the four countries (Fig. 4). Detail review of this area
Fig. 3 Follow-up of the Treatment 2.0 Strategy in Bolivia (28 recommendations)* and El Salvador (12 recommendations)±: perception of the
compliance of recommendations by key informants
Fig. 4 Follow-up of the Treatment 2.0 Strategy in four countries of Latin America. Comparative perception of the compliance of recommendations
related to optimization of antiretroviral regimens and provisions of point-of-care diagnostics*
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showed scores for the recommendation on updating
ART guidelines with an 80–100 % progresses in three of
the four countries (El Salvador was rated at 60 %). The least
progress perceived was related to the recommendation on
plans of communication related to the optimization of ART
regimens (0–60 %) and ART migration plans (30–60 %)
(data not presented).
Limited progress was perceived in the priority area of
provision of POC diagnostic and monitoring tools (less
than 50 % in all the countries; average = 38 %) (Fig. 4).
Although the updating of diagnostic algorithms, with the
inclusion of HIV rapid tests, was the most common rec-
ommendation, it was perceived to have progressed by
only 46 % on average. Meanwhile, the recommendations
with the lowest levels of perceived progress were the
decentralization of monitoring tests (viral load and
CD4), averaging 20 %, and the inclusion of sample trans-
portation strategies, with a perceived 22 % average of
implementation (data not included in the graphic).
No recommendations were made on the ‘adaptation of
delivery services’ priority area for El Salvador. Of the three
remaining countries, Bolivia reported the highest average
progress in this area (average 66 % based on responses from
all key informants), although there was a substantial gap be-
tween interviewees (72 and 78 % for PAHO and NAP re-
spectively, compared to 49 % for civil society). Venezuela
had the lowest average perceived progress in this priority
area (30 %), although civil society did not respond to the
survey. Note that the Venezuelan NAP representatives per-
ceived 60 % progress, while the international cooperation
perceived no progress at all. (Fig. 5). The most frequent rec-
ommendation in this priority area was the decentralization
of health care programs for which the perceived average
implementation was scored at 50 % although this was
reported in only two countries (Bolivia and Ecuador). The
number of recommendations in this priority area was dif-
ferent in each of the four countries: seven recommenda-
tions were made for Bolivia, two for Ecuador, one for
Venezuela and none for El Salvador.
Recommendations on community mobilization were
made in only three countries. Progress achieved in this
priority area was on average 50 %. However, it was not
possible to obtain a realistic view of the implementation
of this priority area in Venezuela and Ecuador since civil
society (the main beneficiaries) did not participate in the
survey, thereby limiting the value of the analysis. Despite
this, Venezuela was perceived to have made progress in
terms of community participation (76 %), followed by
Ecuador (46 %) and Bolivia (40 %). The most frequent
recommendation in this priority area was the need to
implement communication and training strategies for
civil society, designed to improve understanding and
monitoring of the implementation of recommendations
related to the other priority areas. The average progress
of implementation was perceived at 54 % (data not
presented). Implementation of the strategic information
recommendations averaged 50 %. El Salvador and Bolivia
had the highest perception of progress in this priority
area (both with an average of 60 %) (Fig. 5). The most
common recommendations in this area were the inclu-
sion and updating of the HIV information system in the
general health information systems. The implementation
of both recommendations was perceived to have pro-
gressed by an average of 30 %.
Quantitative analysis of the optimization of ARV use
A summary of the results of the analysis of the opti-
mization of antiretroviral use in El Salvador, Venezuela
Fig. 5 Follow-up of the Treatment 2.0 Strategy in four countries of Latin America. Comparative perception of the compliance of recommendations
related to adaptation of delivery services and strategic information*
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and Bolivia is presented in Table 2. The quantitative
analysis shows that there was a 36 % reduction in the
average number of first-line ART regimens in use, from
11 in 2012 to seven in 2013. A similar trend can be
observed for the second-line ART regimens. Over the
same period, the proportion of patients on first-line regi-
mens recommended by WHO increased from 74–78 %
(5.4 % increase). The average use of the preferred WHO
first-line ART regimen [TDF + 3TC (or FTC) + EFV]
increased from 36–43 % (19.4 % increase) between 2012
and 2013 (it should be noted that for this indicator,
results are discordant among countries and in Venezuela
the use of the WHO preferred regimen declined from
63–43 % over the same time period). In addition, aver-
age use of the WHO preferred second-line ART regi-
mens [AZT + 3TC (or TDF + XTC) + LPV/r (or ATV/r)]
increased from 43–65 % (51 % increase) between 2012
and 2013. It is also noteworthy that there was a reduc-
tion in the use of obsolete ARV in first-line regimens. In
2013, only 1 % of people receiving first-line ART were
still on regimens with didanosine (ddl) (no d4T-based
regimen was reported). Finally, a reduction in the use of
obsolete ARVs in second-line regimens was reported
during the period under study. In 2013, 9 % of individ-
uals on second-line ARV were still on regimens with ddl
(no d4T-based regimen was reported).
Discussion
The priority area with the highest number of recommenda-
tions was the optimization of ART regimen, followed by
‘the rational and efficient use of resources’ and provision of
POC diagnostics and monitoring tools. In the optimization
of ART regimens, seven of the eight countries were
recommended to initiate or finalize the process of updating
their national ART guidelines in accordance with the WHO
2013 recommendations. This implies, promoting the use of
simplified, less toxic regimens that maintain therapeutic
efficacy, as well as accelerating the gradual elimination of
obsolete ARV drugs that are no longer recommended. Four
of the eight countries received recommendations on POC
diagnosis and monitoring, underscoring the need to de-
velop and implement HIV diagnostic strategies to include
POC technologies and the decentralization of viral load
and CD4 testing. In the four countries where detailed mon-
itoring of the recommendations was conducted, the highest
proportion of the recommendations was related to the
optimization of ART regimens, and a good level of progress
was perceived in several of the recommendations related to
this area (59.7 % average). This could be explained by the
fact that the countries already had previous experience in
the process of periodic update of their national ARV guide-
lines and in some countries the process was already
undergoing.
The three countries evaluated on the basis of the re-
ported quantitative data show signs of improvement in
the more strategic use of antiretroviral regimens and
drugs. There has been a marked reduction in the
number of first-and second-line regimens, a greater
adherence to the WHO recommendations, especially re-
garding the increased use of the preferred first-line regi-
men, and the almost total withdrawal of obsolete drugs
from the HIV therapeutic arsenal [19]. These same
trends have been observed in many countries of the
Latin American and Caribbean region [13].
With regard to the rational and efficient utilization of
resources, ARVs remain one of the most expensive
Table 2 Optimization of ARVs in the three countries of Latin America, 2012-2013
INDICATOR Year El Salvador Venezuela Bolivia Mean
Number of first-line ART regimens in use 2012 11 14 9 11
2013 12 4 6 7
Percentage of patients in the preferred first-line ART regimens recommended
by WHO (TDF + 3TC (or FTC) + EFV)
2012 85 % 39 % 98 % 74 %
2013 92 % 43 % 99 % 78 %
Percentage of patients in the preferred first-line ART regimens recommended
by WHO (TDF + 3TC [or FTC] + EFV)
2012 9 % 63 % 37 % 36 %
2013 20 % 43 % 66 % 43 %
Percentage of patients in first-line ART regimens including obsolete antiretrovirals
(ddl, d4T, IDV, NFV)
2012 13 % 0 % 1 % 5 %
2013 2 % 0 % 0 % 1 %
Number of second-line ART regimens in use 2012 8 % 18 % 8 % 11 %
2013 10 % 4 % 7 % 7 %
Percentage of patients in second-line ART regimens recommended by WHO 2012 55 % 0 % 74 % 43 %
2013 64 % 50 % 83 % 65 %
Percentage of patients in second-line ART regimens including obsolete ARVs 2012 35 % 1 % 19 % 18 %
2013 20 % 0 % 8 % 9 %
TDF tenofovir dispoproxil fumarate, 3TC lamivudine, FTC emtricitabine, EFV efavirenz, ddl didanosine, d4T Stavudine, IDV indinavir, NFV nelfinavir, WHO World
Health Organization, ARVs antiretrovirals
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components, representing a significant part of the health
budgets of low- and middle-income countries of the
Latin American and Caribbean region. It is important to
ensure the efficient procurement of these drugs. Recent
studies reveal the existence of significant price variations
for ARVs among the countries of the region and oppor-
tunities for cost savings in the procurement of these
essential drugs need to be explored [20]. Efficient resource
utilization signals the need for an integrated approach to
purchasing and delivering ARV. The PAHO Strategic
Fund procurement process is one approach [19].
It is necessary to emphasize that the key informants of
the four countries reported slow progress in the areas
requiring high-level decision-making and investment of
major resources for strengthening the health system or
enhancing multi-sectorial coordination and/or integration.
One example of this is the need to develop and implement
HIV diagnosis strategies that include POC technologies
and the use and decentralization of viral load and CD4
testing (average 38 % perceived progress in the POC
diagnosis and monitoring priority area). Based on the
results of recent evaluations, the increased use of virologic
monitoring as the preferred monitoring approach is
foreseen in the near future [21, 22]. Operational actions
related to deconcentration, decentralization, and the inte-
gration of ART programs at all levels of the healthcare
system have been more difficult to implement, probably
due to the need to involve various multi-sectorial health
areas in a country beyond the National AIDS Programs.
For Latin American countries to adopt the 2013 WHO
consolidated HIV treatment and prevention guidelines,
they will have to invest in the diversification of health
service delivery models in order to cope with increased
volumes of patients and ensure quality of care in the
cascade of care and treatment [23].
When formulating HIV care and treatment policies,
community mobilization approaches are important for
ensuring that the interventions respond to the needs
and circumstances of people at greatest risk and those
living with HIV [24]. The present evaluation concluded
that the average perceived level of progress in the two
countries (where information was available) was near 50 %,
allowing for variations from country to country. The
traditional role of civil society has been critical to the
response of the HIV/AIDS epidemic. It is necessary to
continue to promote and support community mobilization
in order to ensure the sustainability of the response to
HIV/AIDS in the region and assure the involvement of
representatives of civil society in country HIV/AIDS pro-
gram assessments.
Finally, although it is not possible to attribute country
progress of the implementation of the priority areas of
the Treatment 2.0 initiative directly and solely to the
activities of the JRMs, the review of how country
recommendations have been applied suggests that the
JRMs have played a key role by supporting the countries
to create a solid basis for a coordinated response. This is
leading to more rapid expansion of ART coverage and
considering quality of care. In most cases, the country
visits have had a catalyzing effect given that they were
able to bring together key actors at national level and
provide support to reach consensus on national ART
policies.
Potential limitations to the methodology used for
monitoring the recommendations arising from the JRMs
must be acknowledged. Approximately 15 months have
elapsed between the country visits and the present re-
view. We recognize that it is not feasible to accurately
assess the progress achieved in each country concerning
the different Treatment 2.0 priority areas only on the
basis of interviews with key informants. In addition, the
use of a self-reported questionnaire could have allowed
bias in the process of data recording. A third consider-
ation relates to the potential limitations in the progress
rating scales which are dependent on a number of differ-
ent factors such as the local context and the structure of
the questionnaire [25, 26]. In order to mitigate these
limitations, we monitored the recommendations made
by the JRMs by using key informants with knowledge of
a particular community or of a relevant problem area.
To avoid professional [27] and recall bias [28], the in-
formation provided by key informants was validated
through interviews with several different stakeholders: a
representative of the National HIV/AIDS Program, a
civil society representative and an international cooper-
ation representative (PAHO country office). We realize
however that this approach cannot fully ascertain the de-
gree to which the specific recommendations of the JRMs
have been implemented in a particular country. There-
fore we consider the need to undertake periodic moni-
toring visits, using specific and measurable verification
indicators, in order to objectively assess progress in the
implementation of the recommendations. This should
involve developing national plans and improving access
to additional resources such as the Global Fund to Fight
AIDS, Tuberculosis and Malaria [29].
Conclusions
A relatively good level of progress was perceived in
the recommendations related to optimization of ART
regimens. Challenges remain on the improvement of
recommendations related to health system strengthening
and the promotion and support aimed at community-
based organizations as part of the response to HIV/AIDs
in Latin America. Although there is still a need to increase
the impact of the JRMs in the countries, the monitoring
exercise confirms that these missions are a useful mechan-
ism for providing coherent technical support to guide
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countries towards formulating a comprehensive response
to HIV/AIDS in the Latin American region. The results
also suggest that periodic follow-up of the recommenda-
tions of the Treatment 2.0 JRMs is useful and necessary in
order to boost their implementation and detect areas
requiring more programmatic attention and technical
assistance.
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